Advertisement

Digestive Diseases and Sciences

, Volume 64, Issue 10, pp 2992–3000 | Cite as

Early Hepatitis B Surface Antigen Seroclearance Following Antiviral Treatment in Patients with Reactivation of Resolved Hepatitis B

  • Hae Lim Lee
  • Jeong Won JangEmail author
  • Ji Won Han
  • Sung Won Lee
  • Si Hyun Bae
  • Jong Young Choi
  • Nam Ik Han
  • Seung Kew Yoon
  • Hee-Je Kim
  • Seok Lee
  • Seok-Goo Cho
  • Chang-Ki Min
  • Dong-Wook Kim
  • Jong Wook Lee
Original Article
  • 161 Downloads

Abstract

Background and Aims

Long-term results on hepatitis B virus (HBV) reactivation in patients with resolved infection during anti-cancer therapy are unknown. This study investigated long-term risk and therapeutic endpoints including hepatitis B surface antigen (HBsAg) seroclearance following antiviral therapy in patients developing reactivation of resolved HBV.

Methods

The study included 528 consecutive HBsAg-negative/hepatitis B core antibody-positive patients who underwent rituximab treatment or hematopoietic stem cell transplantation (HSCT) between 2006 and 2016. Long-term outcomes of patients with reactivation after antiviral therapy were examined in comparison with 37 HBsAg-positive chronic carriers under the same medical settings.

Results

The 7-year cumulative rate of HBV reactivation was 10.8% and 57.9% in patients receiving rituximab treatment and HSCT, respectively. After antiviral initiation, patients with reactivation of resolved HBV showed significantly higher 1-year cumulative rates of hepatitis B e antigen seroconversion (69.2% vs. 22.6%, P = 0.008) and HBsAg seroclearance (61.8% vs. 3.3%, P < 0.001) than chronic HBsAg carriers. Reactivation of resolved HBV was independently predictive of HBsAg seroclearance in a combined group of reactivated patients and chronic HBsAg carriers. Low viral load at reactivation was predictive of HBsAg seroclearance in reactivated patients. The majority of patients with HBsAg seroclearance developed anti-HBs. None of the reactivated patients who achieved HBsAg seroclearance relapsed after cessation of antiviral therapy.

Conclusions

HBsAg seroclearance rapidly occurs following antiviral therapy for reactivation of resolved HBV infection, suggesting distinct clinical phenotypes as well as shorter duration of HBV infection associated with this particular disease setting-HBV reactivation.

Keywords

HBV reactivation Resolved hepatitis B HBsAg seroclearance Antiviral therapy 

Notes

Funding

This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (NRF-2016R1D1A1B03930457). Study sponsor has no role in study design, in the collection, analysis and interpretation of data.

Author’s contribution

JWJ and HLL were involved in study concept and design, collecting and interpreting data, JWJ, HLL, JWH, SWL, SHB, JYC, NIH, SKY, H-JK, SL, S-GC, C-KM, D-WK and JWL contributed to reagents/materials/analysis tools, and JWJ and HLL wrote the paper. All authors have approved this final version of the manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare no financial conflicts of interest.

References

  1. 1.
    Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605–611.CrossRefGoogle Scholar
  2. 2.
    Hsu C, Tsou HH, Lin SJ, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59:2092–2100.CrossRefGoogle Scholar
  3. 3.
    Han JW, Yang H, Lee HL, et al. Risk factors and outcomes of hepatitis B virus reactivation in hepatitis B surface antigen negative patients with hematological malignancies. Hepatol Res. 2015;46:657–668.CrossRefGoogle Scholar
  4. 4.
    Jang JW, Kim YW, Lee SW, et al. Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma. PLoS ONE. 2015;10:e0122041.CrossRefGoogle Scholar
  5. 5.
    Seto WK. Hepatitis B virus reactivation during immunosuppressive therapy: appropriate risk stratification. World J Hepatol. 2015;7:825–830.CrossRefGoogle Scholar
  6. 6.
    Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68.CrossRefGoogle Scholar
  7. 7.
    Pattullo V. Prevention of hepatitis B reactivation in the setting of immunosuppression. Clin Mol Hepatol. 2016;22:219–237.CrossRefGoogle Scholar
  8. 8.
    Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol. 2014;32:3736–3743.CrossRefGoogle Scholar
  9. 9.
    Vigano M, Vener C, Lampertico P, et al. Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT. Bone Marrow Transpl. 2011;46:125–131.CrossRefGoogle Scholar
  10. 10.
    Park S, Kim K, Kim DH, et al. Changes of hepatitis B virus serologic status after allogeneic hematopoietic stem cell transplantation and impact of donor immunity on hepatitis B virus. Biol Blood Marrow Transpl. 2011;17:1630–1637.CrossRefGoogle Scholar
  11. 11.
    Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: a prospective study. Hepatology. 2017;65:1451–1461.CrossRefGoogle Scholar
  12. 12.
    Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int. 2016;10:1–98.CrossRefGoogle Scholar
  13. 13.
    Hwang JP, Somerfield MR, Alston-Johnson DE, et al. Hepatitis B virus screening for patients with cancer before therapy: American society of clinical oncology provisional clinical opinion update. J Clin Oncol. 2015;33:2212–2220.CrossRefGoogle Scholar
  14. 14.
    Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology. 2010;51:422–430.CrossRefGoogle Scholar
  15. 15.
    Chevaliez S, Hezode C, Bahrami S, Grare M, Pawlotsky JM. Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside/nucleotide analogue therapy: finite treatment duration unlikely. J Hepatol. 2013;58:676–683.CrossRefGoogle Scholar
  16. 16.
    Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis. 2011;204:415–418.CrossRefGoogle Scholar
  17. 17.
    Wursthorn K, Jung M, Riva A, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 2010;52:1611–1620.CrossRefGoogle Scholar
  18. 18.
    Zoutendijk R, Zaaijer HL, de Vries-Sluijs TE, et al. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV. J Infect Dis. 2012;206:974–980.CrossRefGoogle Scholar
  19. 19.
    Seto WK, Wong DK, Fung J, Huang FY, Lai CL, Yuen MF. Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy. Hepatology. 2013;58:923–931.CrossRefGoogle Scholar
  20. 20.
    Jang JW, Yoo SH, Kwon JH, et al. Serum hepatitis B surface antigen levels in the natural history of chronic hepatitis B infection. Aliment Pharmacol Ther. 2011;34:1337–1346.CrossRefGoogle Scholar
  21. 21.
    Cornberg M, Wong VW, Locarnini S, Brunetto M, Janssen HLA, Chan HL. The role of quantitative hepatitis B surface antigen revisited. J Hepatol. 2017;66:398–411.CrossRefGoogle Scholar
  22. 22.
    Fung J, Cheung KS, Wong DK, et al. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance. Hepatology. 2018;68:462–472.CrossRefGoogle Scholar
  23. 23.
    Park YM, Lee SG. Clinical features of HBsAg seroclearance in hepatitis B virus carriers in South Korea: a retrospective longitudinal study. World J Gastroenterol. 2016;22:9836–9843.CrossRefGoogle Scholar
  24. 24.
    Kuo TM, Hu CP, Chen YL, et al. HBV replication is significantly reduced by IL-6. J Biomed Sci. 2009;16:41.CrossRefGoogle Scholar
  25. 25.
    Jang JW, Oh BS, Kwon JH, et al. Serum interleukin-6 and C-reactive protein as a prognostic indicator in hepatocellular carcinoma. Cytokine. 2012;60:686–693.CrossRefGoogle Scholar
  26. 26.
    Prieto J. Inflammation, HCC and sex: IL-6 in the centre of the triangle. J Hepatol. 2008;48:380–381.CrossRefGoogle Scholar
  27. 27.
    Shin EC, Sung PS, Park SH. Immune responses and immunopathology in acute and chronic viral hepatitis. Nat Rev Immunol. 2016;16:509–523.CrossRefGoogle Scholar
  28. 28.
    Sonneveld MJ, Zoutendijk R, Flink HJ, Zwang L, Hansen BE, Janssen HL. Close monitoring of hepatitis B surface antigen levels helps classify flares during peginterferon therapy and predicts treatment response. Clin Infect Dis. 2013;56:100–105.CrossRefGoogle Scholar
  29. 29.
    Li W, Zhao J, Zou Z, et al. Analysis of hepatitis B virus intrahepatic covalently closed circular DNA and serum viral markers in treatment-naive patients with acute and chronic HBV infection. PLoS ONE. 2014;9:e89046.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Hae Lim Lee
    • 1
  • Jeong Won Jang
    • 1
    Email author
  • Ji Won Han
    • 3
  • Sung Won Lee
    • 1
  • Si Hyun Bae
    • 1
  • Jong Young Choi
    • 1
  • Nam Ik Han
    • 1
  • Seung Kew Yoon
    • 1
  • Hee-Je Kim
    • 2
  • Seok Lee
    • 2
  • Seok-Goo Cho
    • 2
  • Chang-Ki Min
    • 2
  • Dong-Wook Kim
    • 2
  • Jong Wook Lee
    • 2
  1. 1.Division of Hepatology, Department of Internal Medicine, College of MedicineThe Catholic University of KoreaSeoulRepublic of Korea
  2. 2.Division of Hematology, Department of Internal Medicine, College of MedicineThe Catholic University of KoreaSeoulRepublic of Korea
  3. 3.Laboratory of Translational Immunology and VaccinologyGraduate School of Medical Science and Engineering, KAISTDaejeonRepublic of Korea

Personalised recommendations